Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • TA228
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Thalidomide in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.

1.2 Bortezomib in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:

  • high-dose chemotherapy with stem cell transplantation is considered inappropriate and

  • the person is unable to tolerate or has contraindications to thalidomide.